Clotting factor replacement therapy
A fact sheet for people with haemophilia, their families and carers on clotting factor replacement therapy.
It explains what it is, how it works, when and how it is given and the ‘half-life’ of concentrates. It includes the different types: standard half-life (SHL), extended half-life (EHL), ultra-long half-life (UHL). It also covers treatment safety (side-effects, inhibitors and risk of infection) and living well with haemophilia treatment.
(October 2025)
Download fact sheet PDF – 568 KB
Acknowledgments
This fact sheet has been funded by unrestricted education grants from CSL Behring and Sanofi. This funding is based on a mutual understanding that HFA will act independently for the benefit of the bleeding disorders community. HFA does not promote any particular pharmaceutical product. Where possible products are referred to by their class or generic name and any mention of any commercial brand is strictly for educational purposes.